Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

Overview

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 30, 2018

Detailed Description

The Relaxation Response Resiliency Program, or 3RP, was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine. The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. The 3RP has not yet been carried out with individuals who have recently completed treatment for lymphoma. As such, the investigators have adapted the standard 3RP program to target the specific needs of lymphoma patients who are transitioning off active treatment. The investigators are conducting this study to see if the adapted program, the 3RP-Lymphoma, is effective at reducing stress and stress-related symptoms for people who have completed treatment for lymphoma within the past two years. To develop the 3RP-Lymphoma, the investigators conducted interviews with patients who had recently completed treatment to learn about their experiences and their preferences for topics they would want to include in a program tailored to their specific needs. The current phase of the feasibility study will examine if the adapted program is feasible, acceptable, and helps promote stress management among lymphoma survivors who are in the early stages of completing cancer treatment.

Interventions

  • Behavioral: 3RP-Lymphoma
    • An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.

Arms, Groups and Cohorts

  • Experimental: 3RP-Lymphoma
    • -An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions
    • Time Frame: 1 month after completing the 3RP-Lymphoma program
    • The investigators will evaluate program feasibility by examining rates of treatment completion. Participants who complete at least 75% of the treatment sessions will be identified as treatment completers.
  • Number of Participants Who Found the 3RP Program Acceptable
    • Time Frame: 1 month after completing the 3RP-Lymphoma program
    • Acceptability will be assessed at the one-month follow up data collection period with five questions on the 3RP acceptability questionnaire rated on a 4-point Likert scale (1=not at all to 4=very much); higher scores mean higher levels of acceptability.

Secondary Measures

  • Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples
    • Time Frame: 1 month after completing the 3RP-Lymphoma program
    • The investigators will explore the feasibility and acceptability of collecting hair samples to examine levels of cortisol, a stress biomarker.

Participating in This Clinical Trial

Inclusion Criteria

  • Aged 18-64 – Within 2 years post-treatment completion for lymphoma – English speaking – Able and willing to provide informed consent – Cancer treatment or follow-up for lymphoma at the MGH Cancer Center Exclusion Criteria:

  • Unwilling or unable to participate in the study – Unable to speak or read English – Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI) – Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software – Participation in qualitative interview during Phase 1 (DF/HCC 16-396)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Massachusetts General Hospital
  • Collaborator
    • American Cancer Society, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Giselle K. Perez Lougee, Instructor in Psychiatry at Harvard Medical School – Massachusetts General Hospital
  • Overall Official(s)
    • Giselle K. Perez, PhD, Principal Investigator, Massachusetts General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.